Ash 2021 movers – IGM steals the show, for all the wrong reasons
At a meeting lacking practice-changing studies and featuring many disappointments the downturn in IGM’s fortunes stands out.
SITC 2021 – Incyte unveils its oral checkpoint blocker
There are some remissions, but peripheral neuropathy casts a long shadow.
What Novartis could buy with its windfall
The group will get nearly $21bn for its Roche stake, and more if it sells Sandoz.
Calithera buys itself a plan B
With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.
Incyte and Seagen face tricky launches
Black box warnings could limit the sales of their newly approved therapeutics.
Go or no go? A first for Nefecon
Calliditas is hoping for its first approval, while Abbvie is gearing up to enter the crowded migraine space with an oral anti-CGRP project.
